HUE032205T2 - Atomoxetin oldat - Google Patents

Atomoxetin oldat Download PDF

Info

Publication number
HUE032205T2
HUE032205T2 HUE13818182A HUE13818182A HUE032205T2 HU E032205 T2 HUE032205 T2 HU E032205T2 HU E13818182 A HUE13818182 A HU E13818182A HU E13818182 A HUE13818182 A HU E13818182A HU E032205 T2 HUE032205 T2 HU E032205T2
Authority
HU
Hungary
Prior art keywords
solution
atomoxetine
range
flavor
raspberry
Prior art date
Application number
HUE13818182A
Other languages
English (en)
Inventor
Matthew S Mermey
Arup Kumar Roy
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49920679&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE032205(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HUE032205T2 publication Critical patent/HUE032205T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (2)

  1. Attanoxeiin oklat SssësdxImL Ígl^ypoííífjk K tí\vxv,*^u Kos^smimVi meK λ \;rxf ;·χ\ mmumex τ mh i 'W* Ff i \ruhcsal Raspfe«rry €A Flavor, &amp; egy édssitdszm iMalÜtó, ultol « gyégyibxaii készítmény orális, vizes pilot jshikú, es az sarába vizes old-aí pH-értéke a ,10 ·· éji tartományban van, és ahol az. annaoset'm konecnt-rádéja: »* L0·* ..lö-mgisnL tartoraám&amp;8ö van, êsa FAÍ999 FFC Artificial Raspberry CA Fiskor ltom eenirádója 1,0-30 m&amp;'mL· tartományban van.,. 2 Az 1. igénypont szeméi gyógy ;iS/«b készítmény, mdy aíomosetint, vizet, nálrmmhenzoátoF nfttn-unvéjhidtogénfesszfát dihid rátok toszimsmat.. szofbUok, xilitolt, F-9999 PFC Artificial Raspberry CA iM&amp;vorsfke^ tartalmaz; ahol azsoräfe vises ddappiidtéke M.Ö Μ,Ο tartomány ban van. I, Αχ 1. s agy 2, igénypont s/crlmi gyógy «s/ab készítmény. ahd momoxetm atÄäMio.-;Är#ÄÄ. 4 A/ M. îgèntpontok bármely tkes/et nth gyógyászati ke»?nmen>, aboi az aíomoxetm Koneenksem" ja a 3 - 6 mg/mL tartományba van, ‘A/M tgeny rontok batmctytke •'/omm gyogyavatí to's/mnem, aboi m emto \;/Cs "kié pH ekéké a 3d - 4„> tartományban van é i bâtas órain; via> oldat tot nőj» gyógyáru kcszmnesn doaitnamnn melynek ,;or,m .itomoxetmi. vrzet, mbrtontoemmátot, nátriom-dihidtogénfosztát dikklrátot. foszforáévá?, s/orbitolí, xilitsdt, F-9999 FFC Λ miied Raspberry ΓΛ Flavor mtsitós/ert óv sznkmio/? kombinálunk. aboi az oldat pH-erteke a 3.7 - 4,3 tartományban van, az atomosét in koncentrációja az 1,0 - 10 mg/mL tartományban van, és a í-9999 pH' AmOdai Raspberry CA Fiav^rÍóaennsAoic|a Í.Odö " \ n goj spont v'tomo eljbas m Ί ab' moot ; „e eovmr Indroklorkl k \ ' vgonspont szs-onts elgeas melynek s ' ,e. tat atomovetm htdrokloridot, náírmmhenzoátuf c\ t rs í it id rxgdíy d í ^ * d| mtcst iidstnik ísszík ton, s dn- m okim keletkmeseíg keverjük, lapidkavat adunk at (a) la péskeít avart atdathosg 4s atdk keiatkaadstig kovasjuk; {c}. pgaddtdt adnák a ih) ^pcsbcn ovesi okknhor. <is okaa kalrtkvsésdsg keveydk; :{é)\ sálitól adunk a (cj lëpésbeïiaaert dldathoz, ds oldat fealotkazàsàlg kavasjPk; (a}. :$*9999 Wß,4#îiflf|â) Rsspkars-y C'â: Havoc laaáíídáaartaduák a (d) làpàsfeass styast ÂA^·# oldat kuíofkoadtóg ka vasfűig ifi aaálrafet adunk, m (à) lipdabyn avast oyatdoys ásóidat' tetatkayasali kavasjök; (g)· aa (f) Mpakbaft ayad oldat :tdgértdkat; xum fosaldatav oldattak às/vagy vtós siktamadddroaid ok : dalia! 3. ? da 4.4 %daötts èrtdkra àil ftjitkp én (It). m:||) !|épiàb#*l tokot adtók, 4,0 · d,ö ssigapL - lít$tóá!tóé'£&amp;&amp;·· a'0îa%âçs6 tasiilf tárásat
  2. 9. Λ d-l. Igdayponfök kfeippány.
HUE13818182A 2013-11-08 2013-12-19 Atomoxetin oldat HUE032205T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361901577P 2013-11-08 2013-11-08

Publications (1)

Publication Number Publication Date
HUE032205T2 true HUE032205T2 (hu) 2017-09-28

Family

ID=49920679

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13818182A HUE032205T2 (hu) 2013-11-08 2013-12-19 Atomoxetin oldat

Country Status (15)

Country Link
US (1) US9326935B2 (hu)
EP (1) EP2838510B1 (hu)
JP (1) JP5973073B2 (hu)
CN (1) CN105705135A (hu)
CY (1) CY1118100T1 (hu)
DK (1) DK2838510T3 (hu)
ES (1) ES2605495T3 (hu)
HU (1) HUE032205T2 (hu)
IL (1) IL244878A (hu)
MX (1) MX365663B (hu)
PL (1) PL2838510T3 (hu)
PT (1) PT2838510T (hu)
SI (1) SI2838510T1 (hu)
TW (1) TWI583402B (hu)
WO (1) WO2014204513A1 (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105726473A (zh) * 2016-03-31 2016-07-06 北京万全德众医药生物技术有限公司 托莫西汀或其可药用盐口服溶液及其制备方法
CN106727291B (zh) * 2016-12-06 2020-02-11 山东达因海洋生物制药股份有限公司 一种盐酸托莫西汀口服溶液及其制备方法
US9855228B1 (en) * 2016-12-14 2018-01-02 Taho Pharmaceuticals Ltd. Oral solution comprising atomoxetine hydrochloride and methods thereof
CN111437247A (zh) * 2019-01-17 2020-07-24 北京万全德众医药生物技术有限公司 一种托莫西汀口服液的制备方法
CN112438949A (zh) * 2019-09-05 2021-03-05 北京兴源联合医药科技有限公司 一种含钙补充剂的盐酸托莫西汀口服液及其制备方法
CN112451476A (zh) * 2019-09-09 2021-03-09 北京兴源联合医药科技有限公司 一种盐酸托莫西汀口服液及其制备方法
CN111956607A (zh) * 2020-09-25 2020-11-20 健民药业集团股份有限公司 盐酸托莫西汀口服溶液及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR75395B (hu) 1980-11-14 1984-07-13 Lilly Co Eli
US5658590A (en) 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
BR0108980A (pt) * 2000-03-07 2003-06-03 Lilly Co Eli Aplicação e formulação farmacêuticas compreendendo inibidor de reabsorção de norepinefrina
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
AU2004312059A1 (en) 2003-12-31 2005-07-21 Actavis Group Hf Atomoxetine formulations
WO2006108120A1 (en) 2005-04-05 2006-10-12 Teva Pharmaceutical Fine Chemicals S.R.L. Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability
CN101155775A (zh) * 2005-04-05 2008-04-02 特瓦药物精化学品股份有限公司 稳定的阿托莫西汀盐酸盐、其制备方法，以及其稳定性分析控制
US20070134277A1 (en) * 2005-12-09 2007-06-14 Children's Medical Center Corporation Pharmaceutical formulation for sulfur-containing drugs in liquid dosage forms
EP1998788A4 (en) 2006-03-01 2011-08-03 Ruey J Yu COMPOSITIONS AND METHODS FOR THE TOPIC TREATMENT OF DERMATOLOGICAL DISORDERS RESPONSIBLE FOR TAR
US20080031932A1 (en) 2006-08-04 2008-02-07 Watson Laboratories, Inc. Transdermal atomoxetine formulations and associated methods
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US20080145318A1 (en) 2006-12-13 2008-06-19 Midha Kamal K Atomoxetine formulations and associated methods
US9629920B2 (en) 2009-12-18 2017-04-25 Exodos Life Sciences Limited Partnership Methods and compositions for stable liquid drug formulations
EP2552200B1 (en) 2010-03-31 2015-10-14 Abela Pharmaceuticals, Inc. Dimethyl sulfoxide (dmso) formulations for treating autism
AU2012272804B2 (en) 2011-06-22 2017-07-06 Vyome Therapeutics Limited Conjugate-based antifungal and antibacterial prodrugs
US9040082B2 (en) 2011-06-24 2015-05-26 K-Pax Pharmaceuticals, Inc. Compositions and methods for treatment of chronic fatigue
US20120128683A1 (en) 2011-11-22 2012-05-24 Shantha Totada R Autism treatment

Also Published As

Publication number Publication date
PT2838510T (pt) 2016-11-23
WO2014204513A1 (en) 2014-12-24
US9326935B2 (en) 2016-05-03
MX365663B (es) 2019-06-10
TW201431567A (zh) 2014-08-16
SI2838510T1 (sl) 2016-11-30
EP2838510A1 (en) 2015-02-25
EP2838510B1 (en) 2016-09-21
DK2838510T3 (en) 2016-12-19
JP2015522624A (ja) 2015-08-06
PL2838510T3 (pl) 2017-09-29
IL244878A0 (en) 2016-05-31
TWI583402B (zh) 2017-05-21
IL244878A (en) 2017-04-30
ES2605495T3 (es) 2017-03-14
MX2016005998A (es) 2016-07-18
CN105705135A (zh) 2016-06-22
JP5973073B2 (ja) 2016-08-23
US20150133562A1 (en) 2015-05-14
CY1118100T1 (el) 2017-06-28

Similar Documents

Publication Publication Date Title
HUE032205T2 (hu) Atomoxetin oldat
JP5085138B2 (ja) 高濃度でミダゾラムを含む製薬組成物
JP2015522624A5 (hu)
EP2680813B1 (en) Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer
EP3003384B1 (en) Oral solution comprising atomoxetine hydrochloride
US9993445B1 (en) Oral solution comprising atomoxetine hydrochloride and methods thereof
CN102014904A (zh) 具有适口味道的去铁酮液体配制品
JP2009256216A (ja) 溶液状態で安定なアムロジピンベシル酸塩内服用液剤
WO2010090236A1 (ja) ヘスペリジン含有組成物
AU2013346766B2 (en) Effervescent tablet
US10772869B1 (en) Pharmaceutical compositions including carvedilol and methods of using the same
TWI684462B (zh) 腫瘤學藥物之口服調配物及懸浮液
US20070110689A1 (en) Oral anaesthetic gel
JP5823131B2 (ja) 防風通聖散含有組成物
JP6653931B2 (ja) レベチラセタム含有ゲル経口医薬組成物
JP4195218B2 (ja) 弱アルカリで安定化される薬剤を含む医薬用液剤
Gade A Review article on Oral Jellies for Pediatrics
US20240197631A1 (en) Atomoxetine oral solution
KR100418210B1 (ko) 모노아민산화물b억제제로구성된제약학적조성물
RU2237478C2 (ru) Антимикробная фармацевтическая композиция
AU2008100233B4 (en) Oral anaesthetic gel
JP2005139173A (ja) ビグアナイド系薬剤を含有するゼリー製剤
AU2004313612A1 (en) Oral anaesthetic gel
AU2011203572A1 (en) Oral anaesthetic gel
JP2009001592A (ja) 弱アルカリで安定化される薬剤を含む医薬用液剤